Project Grant R00HL177820
Award Date
5/1/25
Completion Date
4/30/28
Dollars Obligated
$446K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $5,187,690 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a research program focused on advancing the understanding of ABO(H) blood group antigens and corresponding anti-ABO(H) antibodies. The program aims to define the factors that govern anti-ABO(H) antibody formation and the specific ABO(H) antigen targets responsible for hemolytic transfusion reactions. The research program involves three distinct projects...
This $172,800 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research at Brigham & Women's Hospital Inc. to investigate the role of innate immunity and blood group-positive microbes in regulating anti-ABO(H) antibody production. The key objectives are to 1) define how innate immune factors like galectins impact levels of naturally occurring anti-blood group antibodies, and 2)...
The federal Project Grant award R21HL172497, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the engineering of a lab-on-a-particle platform to measure platelet function. The $225,600 award to the University of Colorado-Denver aims to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction through high-throughput kinetic and equilibrium assays....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $693,423 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant's objective is to develop and validate a microfluidic device capable of purifying platelets while preserving their hemostatic function, with the goal of providing safer platelet transfusions for pediatric and neonatal patients. The 4-year project (5/1/2025 - 2/28/2029) will optimize the efficiency of the...
This Project Grant award for $2,600,114 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to evaluate the role of thiol isomerases (TIs) and oxidant stress in thrombus (blood clot) formation. The key research objectives are to: Determine how oxidants generated in disease states promote specific cysteine modifications in the TI protein disulfide isomerase (PDI), and how these oxidative changes to PDI...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks (formerly Puget Sound Blood Center and Program) to conduct molecular and translational research on the mechanisms of disease in von Willebrand disease and sickle cell disease. The research aims to increase understanding of these blood disorders, identify new biomarkers, and explore potential new...
The federal Project Grant award K99HL175037, totaling $125,658.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research to unravel the mechanisms by which dietary saturated fatty acids drive platelet hyper-activation in obesity. The research aims to determine how fatty acid uptake influences platelet membrane composition, the effects of dietary saturated fatty acids on platelet...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $131,250 to the Vitalant Research Institute (VRI) to investigate the potential for amyloid-beta (Aβ) to be transmitted through blood transfusions, leading to cerebral amyloid angiopathy (CAA) and associated intracerebral hemorrhage. The study aims to (A) assess the prevalence of Aβ pathology markers among blood donors, and (B)...
This federal Project Grant award, issued by the National Heart Lung and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research, provides $674,338 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate the genetic architecture regulating tissue factor (TF) expression and its impact on human bleeding and thrombotic risk. The key objectives are to: 1) Evaluate new transcriptional activators and repressors of the F3 promoter and define rare human genetic variation...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $344,304 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Trustees of Boston University, doing business as Boston University Medical Campus. The grant will fund a research project titled "A Learning Health System Approach to Improve the Effectiveness of Blood Transfusions During Septic Shock" over a period from August 15, 2024 to July 31, 2029. The project aims to investigate treatment...